Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats  by Kannen, Vinicius et al.
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a  b  s  t  r  a  c  t
Fluoxetine  (FLX)  is a drug  commonly  used  as  antidepressant.  However,  its effects  on  tumorigenesis  remain
controversial.  Aiming  to evaluate  the  effects  of  FLX  treatment  on  early  malignant  changes,  we  analyzed
serotonin  (5-HT)  metabolism  and  recognition,  aberrant  crypt  foci  (ACF),  proliferative  process,  microves-
sels, vascular  endothelial  growth  factor  (VEGF),  and  cyclooxygenase-2  (COX-2)  expression  in  colon  tissue.
Male  Wistar  rats  received  a daily  FLX-gavage  (30  mg  kg−1)  and,  a single  dose  of  1,2  dimethylhydrazine
(DMH;  i.p.,  125  mg  kg−1).  After 6  weeks  of FLX-treatment,  our  results  revealed  that  FLX  and  nor-ﬂuoxetine
(N-FLX)  are  present  in  colon  tissue,  which  was  related  to  signiﬁcant  increase  in serotonin  (5-HT)  levels
(P <  0.05)  possibly  through  a blockade  in  SERT  mRNA  (serotonin  reuptake  transporter;  P  < 0.05)  resultingberrant crypt foci
roliferative process
ascular endothelial growth factor
yclooxygenase-2
in  lower  5-hydroxyindoleacetic  acid  (5-HIAA)  levels  (P  <  0.01)  and,  5-HT2C  receptor  mRNA  expressions.
FLX-treatment  decreased  dysplastic  ACF development  (P  <  0.01)  and  proliferative  process  (P  < 0.001)  in
epithelia. We  observed  a signiﬁcant  decrease  in  the  development  of  malignant  microvessels  (P  < 0.05),
VEGF (P  <  0.001),  and  COX-2  expression  (P  < 0.01).  These  ﬁndings  suggest  that  FLX  may  have  oncostatic
effects  on  carcinogenic  colon  tissue,  probably  due  to its  modulatory  activity  on  5-HT  metabolism  and/or
its ability  to reduce  colonic  malignant  events.. Introduction
Fluoxetine (FLX) is a selective serotonin reuptake inhibitors
SSRIs) with controversial effects on carcinogenesis, that was
eported to be ineffective against aggressive T-cell lymphoma
n nude athymic mice, despite the signiﬁcant decrease of such
umors in BALB/c mice, in which it possibly acted on immune sys-
em to inhibit tumor growth (Frick et al., 2008). However, it has
een shown to enhance apoptosis and control cell cycle in Burkitt
ymphoma, in spite of not affecting the viability of non-tumor
eripheral blood mononuclear cells (Serafeim et al., 2003). Mean-
hile, FLX has been reported to promote metastasis formation in
oung transplanted melanoma mice (Kubera et al., 2009).Once FLX is orally administered, it has a direct contact with the
pithelia in the gastrointestinal tract (Arimochi and Morita, 2006),
nducing an increase of serotonin (5-HT) levels by the blockade of
∗ Corresponding author. Tel.: +55 16 3602 3180; fax: +55 16 3602 1068.
E-mail addresses: kannen71@yahoo.com.br, viniciusfmrp@gmail.com,
inicius@daad-alumni.de (V. Kannen).
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serotonin reuptake transporter (SERT) (Bertrand et al., 2008). More-
over, high 5-HT levels have been implicated as promoters of cell
proliferation and tumor growth in colon tissue (Tutton and Barkla,
1986). In accordance with the multiple colon tumor subpopulation
theory (Barkla and Tutton, 1981; Garcia et al., 1999), tumor cell
growth can be dependent or independent of colonic amine hor-
mones, temporal switchover to hormone sensitivity and receptors
activity (Barkla and Tutton, 1981).
We have previously shown that dysplastic aberrant crypt foci
(ACF) induced by 1,2 dimethylhydrazine (DMH) is a well estab-
lished method to study the colon cancer development in rodents
and humans (Garcia et al., 2006; Wong et al., 2002) although, recent
reports have implicated dysplastic ACF as a not predictable and
characterized diagnosis method in human beings, restricting its
applicability in clinical routine (Pinsky et al., 2010). Currently, this
assay has been applied to detect inducer and/or modiﬁers factors
in the early colorectal carcinogenesis (Garcia et al., 2006; Kannen
Open access under the Elsevier OA license.et al., 2011), mainly due to its close relationship with the high cell
turnover through an upward shift in the proliferation zone of the
colonic crypts (Wong et al., 1999, 2002), leading to one of the ﬁrst
steps in the multistage colonic carcinogenesis (Garcia et al., 1999).
V. Kannen et al. / Toxicology Letters 204 (2011) 134– 140 135
Table 1
FLX, Nor-FLX, 5-HT, SERT mRNA, 5-HIAA, and 5-HT2Cr mRNA levels in colon tissues of Wistar rats treated or not with FLX and/or DMH.
Detection CTRL/C CTRL/D FLX/C FLX/D
FLX – – 35.24 ± 27.01 29.39 ± 19.21
Nor-FLX – – 89.09 ± 72.9 52.10 ± 16.22
5-HT 1.72 ± 1.51 0.77 ± 0.27 4.76 ± 2.94* 3.66 ± 1.75b
SERT mRNA 0.19 ± 0.09 0.09 ± 0.07 0.08 ± 0.03* 0.09 ± 0.04
5-HIAA  2.09 ± 0.97 0.79 ± 0.49 0.68 ± 0.19** 0.63 ± 0.04
5-HT2Cr mRNA 0.012 ± 0.01 0.017 ± 0.01 0.00029 ± 0.0003 0.00006 ± 0.00007b
FLX, ﬂuoxetine; Nor-FLX, nor-ﬂuoxetine; 5-HT, serotonin; SERT, serotonin reuptake transporter; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT2Cr, 5-HT-receptor. Mean ± SD,
standard deviation.
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Tb P < 0.05 vs.  CTRL/D.
* P < 0.05 vs.  CTRL/C.
** P < 0.01 vs.  CTRL/C.
A growing body of evidence is increasingly supporting the idea
hat pericryptal colonic stroma (PCCS) activity is related to the high
ryptal cell proliferation rates, since it expresses soluble factors that
romote cancer-favorable transition and ACF development (Garcia
t al., 1999; Kannen et al., 2011; Todaro et al., 2010). PCCS is located
utside but adjacent to the basal lamina of cryptal epithelium in
he lamina propria (Todaro et al., 2010; Valcz et al., 2011) and is
ssociated with high vascular endothelial growth factor (VEGF) and
yclooxygenase-2 (COX-2) expression, contributing to malignant
ngiogenesis and colon cancer development (Liang et al., 2004; Park
t al., 2011; Waldner et al., 2010).
The purpose of the present study was to verify the effects of
LX on 5-HT metabolism and recognition related to early malig-
ant lesions in carcinogenic colon tissue. We  focused on the
ypothesis that FLX activity could endogenous upregulate 5-HT
evels in a joint-activity to prevent dysplastic ACF development,
hich may  be related to the proliferative process in colonic
rypts. We  also investigated this relationship in the modulation
f malignant-microvessels development associated with VEGF and
OX-2 expression within PCCS.
. Materials and methods
.1. Chemicals and solutions
FLX and nor-ﬂuoxetine (N-FLX) were obtained from Research Biochemicals
nternational (Natick, MA,  USA). Moclobemide, used as internal standard (IS), was
cquired from Roche Diagnostics (Mannheim, Germany). LC-grade methanol, ace-
onitrile, hexane, and isoamyl alcohol (P.A. grade) were purchased from J.T. Baker
Phillipsburg, NJ, USA). Triﬂuoroacetic acid ammonium salt (98%) was  purchased
rom Acros Organics (Morris Plains, NJ, USA). Sodium hydroxide was analytical-
rade acquired from Spectrum Chemical MFG. Corp. (New Brunswick, NJ, USA).
uriﬁed water was obtained from a Milli-Q Plus system (Millipore, Milford, MA,
SA). DMH  was  purchased from Sigma (St. Louis, MO,  USA).
.2. Animals
Male Wistar rats (150–160 g) were housed in a room at a mean constant tem-
erature (22 ± 2 ◦C) with a 12-h light–dark cycle. They had free access to standard
ellet chow and water. Experimental protocols were approved by the Animal Care
nd  Use Committee (no. 150/2008) from the Medical School, University of São Paulo.
.3.  Experimental design
Animals were randomly allocated into four groups with six rats in each one.
TRL/C was the control group; CTRL/D received a single dose of DMH (125 mg  kg−1;
ntraperitoneal; i.p.) in the second week from the beginning of the experiment; FLX/C
as given a daily FLX-gavage (30 mg  kg−1) for 6 weeks; FLX/D received daily FLX-
avage and a single dose of DMH. Rats were euthanized after 6 weeks from ﬁrst FLX-
avage. Individual autopsies were subsequently performed, being the colon tissue
iecemeal between frozen pieces (−80 ◦C) and ﬁxed samples in formalin buffered
olution by 24 h, as we  previously described (Garcia et al., 2006; Kannen et al., 2011)..4. Detection of 5-HT and 5-HIAA by HPLC
As we  previously described (Moreira et al., 2007), 5-HT and 5-
ydroxyindoleacetic acid (5-HIAA) were quantiﬁed in frozen colon samples.
hey were quantiﬁed by comparing the peak areas to standard curves by thecomputer program Class-LC 10A (Shimadzu, Japan), being the concentrations
expressed in ng mg−1 of colon tissue.
2.5. Drugs analysis in colon samples by LC–MS–MS
FLX and N-FLX were isolated from colon tissue samples (30 mg)  according to our
own  method adapted (Borges et al., 2009). A Quattro LC triple quadrupole mass spec-
trometer (Micromass, Manchester, UK) was interfaced via an electrospray ionization
(Z-ESI) probe with a Shimadzu (Kyoto, Japan) liquid chromatography, equipped with
a  LC-AT VP solvent pump unit. FLX, N-FLX, and IS were separated on LiChrospher®
100 PR-8, 5 m,  125 mm × 4 mm column (Merck, Darmstadt, Germany). A C8 guard
column (4 mm × 4 mm i.d., Merck) was used. Samples were separated under iso-
cratic conditions using a mobile phase consisted of acetonitrile:0.1% triﬂuoroacetic
ammonium acetate aqueous solution (60:40, v/v), at a ﬂow rate of 1.3 mL min−1.
Quantiﬁcation was performed by multiple reaction monitoring (MRM)  of the pre-
cursor ions and their corresponding product ions. The precursor-to-product ion
transitions were monitored at m/z 310 > 44 for FLX, m/z 296 > 134 for N-FLX, and
m/z  269 > 182 for IS. A MassLynx data sampling and processing system (Micromass)
version 4.1 was used.
2.5.1. Calibration solutions
Stock solutions of FLX and N-FLX containing 200 g mL−1 were prepared in
methanol. IS solution was prepared in methanol at 0.10 g mL−1. Calibration curves
were obtained by analyzing spiked colon samples in duplicate over the concentra-
tion range of 6–500 ng of the drug per mg of colon.
2.6. Real-time reverse transcription-polymerase chain reaction
Total RNA was  extracted from frozen colon tissue samples (30 mg)  using Trizol
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. In the
quantitative real-time PCR (qPCR), data were continuously collected and analyzed
using ABI-7500 SDS software package. Total RNA input was  normalized based on
Ct values for GAPD housekeeping gene, as a reference standard. GAPD assay ID was
4352338E (Applied Biosystems). DNASTAR software (version 3.0) was used to design
the primers sequence to amplify 253 and 197 bp of 5-HT2C (NM 012765) and SERT
(NM 013034.3), that were ampliﬁed respectively using SiberGreen reagent (Applied
Biosystems, Foster City, CA, USA). All reactions were duplicated, according to the
standard 7500 software PCR program. The fold change was calculated using 2−Ct
method.
2.7. Histopathological analysis in colonic epithelia
The standard procedure was applied to identify and quantify the dysplastic ACF-
I  (index) in epithelia, and microvessels in PCCS. They were both performed by a
pathologist as described elsewhere (Kannen et al., 2011; Skinner et al., 1995).
2.8. Immunohistochemistry (IHC)
As we previously described (Kannen et al., 2011), primary antibodies were pro-
vided by Novocastra®: NCL-SEROTp (1:100), NCL–PCNA (clone PC 10 at 1:100),
SCB–VEGF (clone A-20 at 1:100), and NCL–COX-2 (clone 4H12 at 1:200). Posi-
tive  reactions were detected in longitudinal sections as a brown precipitate in the
nucleus for proliferative cellular nuclear antigen (PCNA) and in cytoplasm and/or
perinuclei for SEROT (5-HT), VEGF-Li, and COX-2-Li. Cryptal proliferative cell index
(PCNA-Li, labelling index) were expressed in each sample according to total cell
number related to positive cells. To determine VEGF-Li and COX-2-Li scores in PCCS,
the same criteria were applied. Staining procedure with anti-SEROT antibody was
carried out to clarify its location in colon tissue. Analyses were performed by two
independent observers, to avoid intraobserver bias.
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Dig. 1. Anti-SEROT (5-HT) antibody was  applied at colon tissue sections, as a broad
ainly  detected among stroma cells within pericryptal colonic stroma (PCCS) and, m
n  crypts (400×; scale bars 20 m).  (A) SEROT (+) cell is indicated by the arrow (hig
.9. Statistical analysis
Data were analyzed using the statistical program GraphPad Prism 5 (Graph Pad
oftware Inc., San Diego, CA, USA). Data were analyzed by two-way ANOVA test with
onferroni post hoc test. However, for ACF and drug concentrations analysis, an
npaired t test was applied. Probability of P < 0.05 was  considered to be statistically
igniﬁcant.
. Results
.1. FLX and N-FLX modulate 5-HT and 5-HIAA levels through
erotonin enteric transporter (SERT) in colon tissue in vivoAs shown in Table 1, FLX and Nor-FLX levels in colon tissue of
ats given FLX by 42 days did not reveal any difference between
MH or non-DMH treated rats. As expected, FLX treatment signif-rum antibody to serotonergic activity. As indicated by the arrow, 5-HT activity was
 near to the crypt bottom, despite this, positive cells were detected in less extension
niﬁcation).
icantly increased 5-HT levels at samples of colon tissue (P < 0.05)
and signiﬁcantly reduced SERT mRNA expression and 5-HIAA lev-
els at non-DMH treated group (P < 0.05 and P < 0.01). DMH treated
rats that received FLX revealed a strong downregulation of 5-HT2C
receptors mRNA expression (P < 0.05). Anti-5-HT antibody shows,
which serotonergic activity is mainly occurring in stroma cells
within PCCS (Fig. 1). Moreover, DMH-treatment alone reduced SERT
mRNA and 5-HIAA levels in colon tissue to the same levels detected
in FLX-treated groups.
3.2. FLX controls over dysplatic ACF and microvessels
development
FLX has been shown to be an oncostatic agent (Stepulak et al.,
2008; Tutton and Barkla, 1982). However, its potential against the
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Fig. 2. (A) Dysplastic aberrant crypt foci (ACF) is pointed by the arrow. The ﬁgure shows elongated cryptal luminal opening, crowded and pseudostratiﬁed nuclei, less nuclear
polarity, numerous mitoses and lower number of globet cells (magniﬁcation 400×; scale bars 20 m).  (B) ACF-i (index) was demonstrated per m2 of colon mucosa in
animals treated with 1,2 dimethylhydrazine (DMH). P values were determined by Mann–Whitney test (P < 0.01 vs. CTRL/D). (C) Proliferative cellular nuclear antigen (PCNA)
(+)  cells are shown by the arrow (400×; scale bars 20 m).  (C.A) PCNA (+) cell is indicated by the arrow (high magniﬁcation). (D) Proliferative process in colonic crypt cells
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according to PCNA-Li (labelling index; P < 0.01 vs.  CTRL/C; P < 0.001 vs.  CTRL/D). (E) C
eading towards them (400×, bars 20 m).  (E.A) Microvessel towards crypt area is 
er  m2 of colon tissue (P < 0.05 vs.  CTRL/D). Bars and whiskers: mean ± SD (standar
evelopment of preneoplastic injuries is not well characterized. In
his way, dysplastic ACF (Fig. 2A) and crypt proliferative activity
Fig. 2C) were decreased in carcinogenic FLX-treated rats (P < 0.007
nd 0.001; Fig. 2B and D), despite its activity in the promotion of
roliferation in non-carcinogen treated rats (P < 0.01).
.3. FLX controls over proliferation and COX-2 protein
As previously shown (Liang et al., 2004; Waldner et al., 2010),
ysplastic ACF development is also related to microvessels enlarge-
ent. Therefore, crypt surrounding microvessels (Fig. 2E) were
educed in carcinogenic FLX-treated rats (P < 0.05; Fig. 2F). Also, it
ecreased VEGF expression within PCCS (Fig. 3A) in DMH-treated
ats (P < 0.001; Fig. 3B) and, reduced COX-2 expression (Fig. 3C) in
on-DMH and DMH-treated groups (P < 0.01; Fig. 3D).
. Discussion
In this study we demonstrated that FLX and its metabolite are
resent in the colon tissue and this treatment possibly increased 5-
T levels by decreasing SERT activity resulting in the suppression of
-HIAA release. Thus, FLX was quickly diffused into multiples body-
ites, as colon, due to its high lipophilicity (Lefebvre et al., 1999)
nd possibly blocked SERT-function (Gill et al., 2008), resulting inc longitudinal sections reveal the presence of microvessels surrounding crypts and
ted by the arrow (high-magniﬁcation). (F) Microvessel-i (index) was demonstrated
iation). P values were determined by two-way ANOVA and Bonferroni post hoc test.
the imbalance of 5-HT metabolism (Bertrand et al., 2010). Despite
the current knowledge that high 5-HT levels are implicated in the
induction of cell proliferation and tumor growth (Arends et al.,
1986), 5-HT selectively inhibited the colon adenocarcinoma growth
by constricting tumor arterioles (Lubbe and Huhnt, 1994). Further-
more, FLX has been revealed as a great apoptosis inducer inhibiting
tumor development (Arimochi and Morita, 2006; Lee et al., 2010).
Our analysis is driven by the hypothesis that besides FLX effect
on the upregulation of 5-HT levels, their co-related activity possi-
bly promoted the blockade of 5-HT2C receptors. On  the other hand,
endogenous upregulation in this amine levels seemed not to be cor-
related to the promotion of malignant crypt changes, as noticed by
its metabolism and recognition. FLX and N-FLX have been shown
to enhance the rate of desensitization in 5-HT-receptors (Brink
et al., 2004; Choi et al., 2003), reducing both Na+ and Ca2+ cur-
rents as a noncompetitive antagonism activity (Eisensamer et al.,
2003). Also, 5-HT potentially desensitized 5-HT2C receptors after
a short cell exposition to this amine (Briddon et al., 1998), and the
blockade of 5-HT1 and 5-HT2-receptors subtypes inhibited tumor
cell proliferation (Tutton and Barkla, 1980, 1986). Additionally,
5-HT treatment promoted tumor but not crypt cell proliferation
(Tutton and Barkla, 1980), whereas colon tumor cells treated with
sulforaphane revealed decreased 5HT1A, 5-HT2C, and SERT levels,
suggesting a lower tumor progression (Mastrangelo et al., 2008).
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Fig. 3. (A) Vascular endothelial growth factor (VEGF) (+) cells are shown by the arrow (200×; scale bars 20 m).  (A.A) VEGF (+) cell at microvessel wall is indicated by the
arrow  (high magniﬁcation). (B) VEGF-Li according to labelling index of cells for anti-VEGF antibody (P < 0.001 vs.  CTRL/D). (C) Cyclooxygenase-2 (COX-2) (+) cells within
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Although FLX greatly controlled dysplastic ACF development,
he results regarding epithelia proliferation seemed to be con-
icting between non-DMH and DMH  treated rats that received
LX. Such perspective readily implies a potential and complex dif-
erentiating activity between non-malignant and malignant cells,
s previously reported (Serafeim et al., 2003). Based on previ-
us observations about 5-HT activity in crypt proliferative activity
Tutton and Barkla, 1980), this trend towards increasing crypt cells
roliferation in FLX given rats seems to be not directly correlated
o serotonin activity, since its metabolism and recognition (data
ot shown) were blocked and its endogenous upregulation did
ot promote malignancy among carcinogen-treated rats. Further-
ore, this preventive FLX activity against the repopulation of colon
umors is possibly corroborated by the requirement of tumor cells
o take up 5-HT before being stimulated by it (Barkla and Tutton,
981; Tutton and Barkla, 1987). Tutton and Barkla reported that FLX
ecreased the tumor growth as well as, the crypt proliferative activ-
ty in animals under DMH-treatment (Tutton and Barkla, 1982), in a
irect relationship with 5-HT-receptors blockade (Tutton and Steel,
979). Stepulak et al. have shown that FLX diminished the prolifera-
ion of colon tumor cells in vitro by increasing the expression of cell
ycle inhibitors p53 and p21 associated with the lower expression
f cyclin D1 and A (Stepulak et al., 2008).
The present role of FLX in the control of dysplastic ACF
nd microvessels development, related to lower VEGF expression
ithin PCCS, are also pointing that the endogenous upregulation
f 5-HT levels has a potential activity against early malignant
njuries. Whereas, previous reports were quite clear about the sup-
ly of tumors by preexisting host microvessels since their earlyted by the arrow (high magniﬁcation). (D) COX-2-Li according to labelling index of
tandard deviation). P values were determined by two-way ANOVA and Bonferroni
development (Skinner et al., 1990) and, 5-HT-receptors are not
only associated with the control of malignant proliferation, like-
wise implicated to tumor microvascular process (Froberg et al.,
2009; Sulaiman et al., 2008). It seems reasonable that 5-HT applied
intratumorally effectively constricted tumor microvessels (Huhnt
and Lubbe, 1995), and 5-HT combined with bioactive substances
decreased colon carcinoma development by lowering blood ves-
sels density (El-Salhy and Sitohy, 2002; El-Salhy et al., 2003). In
addition, FLX has previously been shown to decrease VEGF plasma
levels in splenic lymphocytes in aged rats (Kubera et al., 2009).
According to our COX-2 protein expression data, we  are sug-
gesting that there is an interaction between FLX and serotonergic
activity, possibly downregulating 5-HT-receptors among stroma
cells. Jin et al. have shown that FLX strongly suppressed proin-
ﬂammatory markers, such as COX-2 in neuronal cells (Jin et al.,
2009) and also decreased proinﬂammatory properties in peri-
toneal macrophages, redirecting them towards anti-inﬂammatory
activity (Roman et al., 2009). It has been reported that DOI (1-[2,5-
dimthoxy-4-iodophenyl]-2-aminopropane) treatment activated
5-HT2C receptor, stimulating COX-2 mRNA and protein expres-
sion (Mackowiak et al., 2002). Moreover, 5-HT-receptors have been
shown to activate cyclic adenosine monophosphate (cAMP) for-
mation (Amireault and Dube, 2005), which in turn phosphorylates
Src and subsequently activates ERK1/2 upregulating COX-2 activ-
ity (Mastrangelo et al., 2008). Previous researches have shown
that overexpression of COX-2 and VEGF factors can support the
development of colon cancer, establishing a link between inﬂam-
matory process and malignant angiogenesis (Liang et al., 2004;
Waldner et al., 2010). Thus, antiangiogenic therapies have been
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uggested as successful strategies to control malignant develop-
ent (Wang et al., 2008).
Our collective data suggest that FLX is a remarkable oncostatic
gent that acts against the development of dysplastic ACF possibly
ue to its inhibitory effect on malignant proliferation and angiogen-
sis. Therefore, FLX activity is possibly associated with high 5-HT
evels, blocking the colonic serotonergic metabolism and recogni-
ion, as a possible adjunct-factor against the malignant changes.
ccording to our present ﬁndings in colonic epithelia and PCCS,
e believe that FLX might control the carcinogenic interaction
etween crypt cells and surrounding stroma elements, controlling
icrovessels development, VEGF, and COX-2 expression. Despite
ur results indicate that FLX may  control preneoplastic develop-
ent in colon tissue, further studies should be accomplished.
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